Cargando…
Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice
BACKGROUND: Stroke is a major cause of morbidity and mortality. Stroke is complicated by brain edema and blood-brain barrier (BBB) disruption, and is often accompanied by increased release of arginine-vasopressin (AVP). AVP acts through V1a and V2 receptors to trigger hyponatremia, vasospasm, and pl...
Autores principales: | Zeynalov, Emil, Jones, Susan M., Seo, Jeong-Woo, Snell, Lawrence D., Elliott, J. Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537303/ https://www.ncbi.nlm.nih.gov/pubmed/26275173 http://dx.doi.org/10.1371/journal.pone.0136121 |
Ejemplares similares
-
Recent advances and future directions in preclinical research of arginine-vasopressin (AVP) receptor blocker conivaptan in the context of stroke
por: Zeynalov, Emil, et al.
Publicado: (2016) -
Therapeutic time window for conivaptan treatment against stroke-evoked brain edema and blood-brain barrier disruption in mice
por: Zeynalov, Emil, et al.
Publicado: (2017) -
Development and validation of an HPLC–MS/MS method for the determination of arginine-vasopressin receptor blocker conivaptan in human plasma and rat liver microsomes: application to a metabolic stability study
por: Alrabiah, Haitham, et al.
Publicado: (2018) -
Arginine Vasopressin, Synaptic Plasticity, and Brain Networks
por: Marcinkowska, Anna B., et al.
Publicado: (2022) -
Blockade of Arginine Vasopressin receptors prevents blood-brain barrier breakdown in Experimental Autoimmune Encephalomyelitis
por: Viñuela-Berni, Verónica, et al.
Publicado: (2020)